ADVANCE (Accelerate the Development of Vaccines and New Technologies to Combat the AIDS Epidemic), funded by a cooperative agreement through 2026 with the U.S. Agency for International Development (USAID) through the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), aims to end HIV in partnership with Africa. Building on IAVI’s long-term partnership with USAID, ADVANCE partners include a network of African and Indian clinical research centers and the Human Immunology Laboratory at the Imperial College London.
ADVANCE is cultivating a core group of researchers and scientists in African institutions, to participate in the global effort to identify, evaluate, and implement HIV vaccines and biomedical prevention products in the fight against HIV. Together with its partners, IAVI provides research and technical assistance in implementing clinical trials, helps build capacity in transfer of technology, and leverages partnerships to build lasting vaccine research and development capacity on the continent. With ADVANCE, the results of community epidemiology studies can be applied to advance the development of an effective HIV vaccine or other biomedical prevention tools.
ADVANCE has four areas of focus:
- Evaluating HIV vaccine and bnAb candidates in clinical trials.
- Leading the design and testing of vaccine immunogens and broadly neutralizing antibodies (bnAbs) through Africa-centered science.
- Understanding communities and cohorts involved in epidemiology studies, social behavioral research studies, and community engagement/research preparedness.
- Strengthening sustainable capacity of scientists and institutions and transferring critical technologies and information.